Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open Label Study to Evaluate the Safety of Copaxone and to Monitor the Neurologic Course of Disease in Multiple Sclerosis Patients Treated With Copaxone

Next Previous
X
Search
Trial Profile

Open Label Study to Evaluate the Safety of Copaxone and to Monitor the Neurologic Course of Disease in Multiple Sclerosis Patients Treated With Copaxone

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Sep 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Glatiramer acetate (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Teva Branded Pharmaceutical Products R&D; Teva Neuroscience; Teva Pharmaceutical Industries

    • Most Recent Events

    • 08 Sep 2022 Results of an analysis of OLE part comparing effectiveness of early start versus delayed start with Glatiramer acetate published in the Multiple Sclerosis Journal
    • 06 Nov 2018 Status changed from active, no longer recruiting to completed.
    • 12 Oct 2018 Results of long term 25 years presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top